CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


RadiotherapyWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)


Name (Synonyms) Correlation

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.06

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.06

There is one clinical trial.

Clinical Trials


1 Low Dose Radiotherapy as Antinflammatory Treatment for COVID-19 Pneumonitis

SARS-CoV-2 is causing an unprecedented stress on healthcare systems around the world, due to its high rate of infection and the high morbidity and mortality. The COVID-19 infection triggers an inflammatory cascade with cytokine synthesis, prompting the immune response. Low dose radiotherapy (LD-RT) (≤ 100 cGy) induces an anti-inflammatory response, lowering levels of pro-inflammatory cytokines such as IL-1β or inhibit leukocyte recruitment. LD-RT has been used historically for the pneumonia treatment reporting a rapid clinical improvement (within the first week), as well as a reduced mortality (from around 30% to 10%). Considering these results, LD-RT can potentially afford a therapeutic benefit against SARS-CoV-2. The study purpose is to evaluate prospectively the safety and efficacy of LD-RT for SARS-CoV-2.

NCT04420390 Covid19 Radiation: Radiotherapy
MeSH:Pneumonia
HPO:Pneumonia

Primary Outcomes

Description: Radiological results: Radiological worsening, improvement or without significant changes

Measure: Radiological response

Time: 3 days after low dose radiation

Description: Radiological results: Radiological worsening, improvement or without significant changes

Measure: Radiological response

Time: 7 days after low dose radiation

Secondary Outcomes

Description: Remission of respiratory symptoms

Measure: Remission of respiratory symptoms

Time: up to 6 months

Description: Time to SPO2>94% or PaO2/FiO2 >350mmHg without oxygen

Measure: SPO2 and PaO2/FiO2

Time: 7 days

Description: Occurrence and grade of CTCAE 5.0 adverse events

Measure: Adverse events

Time: 1 year

Description: Duration of hospitalization

Measure: Hospitalization

Time: 3 months

Description: Overall survival

Measure: Overall survival

Time: 1 month

Description: ferritin value (ng/mL)

Measure: Ferritin value

Time: 1 day after low dose radiation

Description: ferritin value (ng/mL)

Measure: Ferritin value

Time: 2 days after low dose radiation

Description: ferritin value (ng/mL)

Measure: Ferritin value

Time: 3 days after low dose radiation

Description: blood cell count (unit/L)

Measure: blood cell count

Time: 1 day after low dose radiation

Description: blood cell count (unit/L)

Measure: blood cell count

Time: 2 days after low dose radiation

Description: blood cell count (unit/L)

Measure: blood cell count

Time: 3 days after low dose radiation

Description: C-reactive protein (mg/dl)

Measure: C-reactive protein

Time: 1 day after low dose radiation

Description: C-reactive protein (mg/dl)

Measure: C-reactive protein

Time: 2 days after low dose radiation

Description: C-reactive protein (mg/dl)

Measure: C-reactive protein

Time: 3 days after low dose radiation

Description: D-dimer (ng/ml)

Measure: D-dimer

Time: 1 day after low dose radiation

Description: D-dimer (ng/ml)

Measure: D-dimer

Time: 2 days after low dose radiation

Description: D-dimer (ng/ml)

Measure: D-dimer

Time: 3 days after low dose radiation

Description: LDH levels (UI/L)

Measure: LDH levels

Time: 1 day after low dose radiation

Description: LDH levels (UI/L)

Measure: LDH levels

Time: 2 days after low dose radiation

Description: LDH levels (UI/L)

Measure: LDH levels

Time: 3 days after low dose radiation


Related HPO nodes (Using clinical trials)